Aldeyra Therapeutics, Inc. ALDX
Set alert
0.56 USD -0.10 -14.99%
At close · Oct 30
0.56 0.00 -0.05%
After hours · Oct 30, 4:14 PM ET
0.5502 Day range 0.68
0.5603 52-week range 5.62
- YTD
- -89.18%
- 1 year
- -88.86%
- Open
- 0.67
- Prev close
- 0.6591
- Mkt cap
- 33.80M
- Vol
- 896.63K
- Avg vol
- 1.15M
- EPS
- -0.38
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5502
- High
- 0.68
- Forward P/E
- -7.80
- Beta
- 1.43
- Short ratio
- 6.19
- Inst. own
- 62.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 3, 2024
- 50-d avg
- 5.12
- 200-d avg
- 4.48
- 1y target
- 10.00
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.25; estimate -0.25; surprise 0%
Signals (83)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 29, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 3 days ago |
| RSI: Oversold | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| RSI: Oversold | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 9 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 24, 2025 | 10 months ago |
| SMA: Bearish | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 18, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 16, 2025 | 10 months ago |
| SMA: Bullish | Dec 16, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| RSI: Oversold | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Dec 2, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 12, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| SMA: Bearish | Oct 22, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 26, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| RSI: Overbought | Aug 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| RSI: Overbought | Jun 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 17, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| RSI: Overbought | Feb 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 22, 2025 | 1 year ago |
| SMA: Bearish | Jan 16, 2025 | 1 year ago |
| SMA: Bullish | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 19, 2024 | 1 year ago |
Key statistics
- Market cap
- 283.16M
- Enterprise value
- 233.47M
- Trailing P/E
- 0.00
- Forward P/E
- -7.80
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.33
- EPS (TTM)
- -0.75
- Beta
- 1.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -57.67M
- Total cash
- 72.74M
- Total debt
- 15.61M
- Return on equity
- -43.05%
- Shares outstanding
- 59.55M
- Short % of float
- 6.90%
- 50-day average
- 5.12
- 200-day average
- 4.48
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.00 +1684.8% upside
Now 0.5603
- Target (low)
- 8.00
- Target (mean)
- 10.00
- Target (high)
- 12.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 3, 2024
Expected Oct 3, 2024. Consensus EPS estimate -0.21731.
Financials — quick view
ALDX Revenue — quarterly 0
ALDX Net income — quarterly -5.45M
ALDX EPS — quarterly -0.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.25 | -0.25 | 0.00 | 0.00% |
| Oct 3, 2024 | Jun 1, 2024 | -0.21 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.08 | -0.14 | -0.06 | -75.00% |
| Mar 7, 2024 | Dec 1, 2023 | -0.21 | -0.08 | +0.13 | +61.90% |
| Nov 3, 2023 | Sep 1, 2023 | 0.00 | -0.14 | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -0.31 | -0.15 | +0.16 | +51.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 6, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 3, 2024 | Oppenheimer | up | Perform | Outperform |
| Oct 17, 2023 | Citigroup | main | Buy | Buy |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aldeyra.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target
- Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
- Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
- Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
- BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
- Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
- Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Your note
Sign in to keep a note on ALDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADY TODD C | Chief Executive Officer | Sale | Mar 11, 2024 | 1,471,300 |
| BRONSTEIN BEN | Director | Conversion of Exercise of derivative security | Jun 26, 2023 | 28,248 |
| GREENBERG BRUCE | Chief Financial Officer | Sale | Aug 11, 2024 | 126,382 |
| MACHATHA STEPHEN | Officer | Sale | Aug 11, 2024 | 236,771 |
| MILLER-RICH NANCY | Director | Purchase | Apr 11, 2023 | 922 |
| PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 4, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 15.58% | 9,275,851 | 44.11M | Sep 29, 2024 |
| Knoll Capital Management, LLC | 9.19% | 5,475,516 | 26.04M | Sep 29, 2024 |
| Vanguard Group Inc | 6.32% | 3,760,619 | 17.88M | Sep 29, 2024 |
| Blackrock Inc. | 6.27% | 3,734,408 | 17.76M | Sep 29, 2024 |
| Kennedy Capital Management, Inc. | 3.16% | 1,881,078 | 8.94M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.87% | 1,114,628 | 5.30M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 1,758,714 | 8.36M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.18% | 1,296,318 | 6.16M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 697,567 | 3.32M | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 1.14% | 680,004 | 3.23M | Jul 30, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 1.07% | 635,905 | 3.02M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 510,128 | 2.43M | Aug 30, 2024 |